AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01425632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02369471
Drug: GWP42006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00629031
Drug: Paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 11 mg/kg for 14 days
Trial: NCT04055168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
Trial: NCT02369471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00129935
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00129935
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03514615
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The incision site on the other arm will be dosed with placebo gel.
Trial: NCT03076905
Drug: F901318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of AUC0-t
Trial: NCT02797522
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
Trial: NCT00629031
Drug: Paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin for 21 days @ 11mg/kg by intramuscular injections
Trial: NCT03159585
Drug: TAEST16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
Trial: NCT02710331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: no alcohol, administered for \~80 minutes.
Trial: NCT02710331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Placebo pill (no active cannabinoids) administered orally.
Trial: NCT02710331
Drug: Active Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Trial: NCT00551330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of placebo once daily
Trial: NCT02330094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Trial: NCT03487198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2-3 mg/day
Trial: NCT04645524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule administered before bed
Trial: NCT00786201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
Trial: NCT00786201
Drug: CNTO 888 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Trial: NCT00786201
Drug: CNTO 888 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Trial: NCT00786201
Drug: CNTO 888 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Trial: NCT00363896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
Trial: NCT00999505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice a day over 12 weeks
Trial: NCT00081575
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003877
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01168063
Drug: standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)
RxNorm normalized name: pantoprazole, amoxicillin, clarithromycin and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 lines of treatments :~1) PPI + Amoxicillin + Clarithromycin for 7 days~1) PPI + Amoxicillin + Metronidazole for 14 days
Trial: NCT00560144
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg iv weekly
Trial: NCT00560144
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9mg/kg iv weekly
Trial: NCT00560144
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
Trial: NCT04481685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill will be taken twice daily preferably spaced 12 hours apart.
Trial: NCT00136643
Drug: Invisible Condom®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04341129
Drug: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem
Trial: NCT00806481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group: treatment with tablets of placebo three times daily for 36 weeks
Trial: NCT00708318
Drug: i.v. fentanyl and AeroLEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN.
Trial: NCT01428427
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
Trial: NCT03822429
Drug: Controlled ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal therapy to induce ovulation by multiple ovarian follicles
Trial: NCT00504777
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg/week po or parenteral
Trial: NCT00416195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00505154
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10 mg tablets od for 6 months
Trial: NCT00505154
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04154852
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01417104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg/300mg
Trial: NCT00639522
Drug: Liposomal paclitaxel and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
Trial: NCT02718261
Drug: Saline 0.9% (matching placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01589159
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug:capecitabine 700mg/m2, twice daily on days 1-14.
Trial: NCT04089189
Drug: IMP4297
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP4297 100mg PO QD
Trial: NCT01055847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Placebo
Trial: NCT03274895
Drug: PHMB 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Trial: NCT03508804
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml of vaginally self-administered placebo cream
Trial: NCT01435044
Drug: Placebo to match GS-0938
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GS-0938 administered orally once daily
Trial: NCT04012177
Drug: Azithromycin Tablets
RxNorm normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
Trial: NCT01501422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch for 8 weeks
Trial: NCT04012177
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
Trial: NCT02927353
Drug: DMB-3113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously injected in a single dose of 40 mg.
Trial: NCT01987492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
Trial: NCT00757627
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 mg QD for 4 weeks.
Trial: NCT01133080
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
Trial: NCT01133080
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
Trial: NCT00002653
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00536653
Drug: Bicalutamide and Calcium/ Vitamin D supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
Trial: NCT00536653
Drug: LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
Trial: NCT01912404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo controlled
Trial: NCT00309257
Drug: ACE I, ATA II and Statins
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00499967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GS-9191 ointment
Trial: NCT00309257
Drug: Benazepril, Valsartan and Fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate.
Trial: NCT03054740
Drug: Nature's Tears
RxNorm normalized name: Nature's Tears
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water mist will be administered 1-2 sprays prior to intravenous access
Trial: NCT03156855
Drug: 14-day sequential therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
Trial: NCT01327846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01327846
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
Trial: NCT00219479
Drug: Phenytoin (Dilantin) levels during change in enteral feeding
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01843725
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: escalation dose of capecitabine continuously
Trial: NCT01843725
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
Trial: NCT01635023
Drug: AZD6244 Dosing Period 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A, B, or C depending on randomization assignment
Trial: NCT01079910
Drug: isopropylmethylphenol and Fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% isopropylmethylphenol and 1150ppm fluoride
Trial: NCT02448329
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3
Trial: NCT02714283
Drug: inhaled corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
Trial: NCT02714283
Drug: macrolide therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
Trial: NCT01509547
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Trial: NCT03365947
Drug: ARO-HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc injection
Trial: NCT00594880
Drug: Pegylated Interferon-alpha 2a, 180 mcg/week sc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Trial: NCT00594880
Drug: Pegylated Interferon-alpha 2a, 90 mcg/week sc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
Trial: NCT00006158
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02387554
Drug: HGP0904
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02387554
Drug: HGP0608
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02387554
Drug: HGP1405
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02142153
Drug: F901318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile
Trial: NCT02142153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
Trial: NCT00022737
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00022737
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00022737
Drug: mercaptopurine tablet
RxNorm normalized name: Mercaptopurine Tablets
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00022737
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, and orally
Trial: NCT00003483
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT00180908
Drug: Etoposide, Ifosfamide, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00180908
Drug: Doxorubicin, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02280876
Drug: 1 - Andrographis paniculata p/st extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile.
Trial: NCT04744753
Drug: Calcium Ionophore A23187
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF.
Trial: NCT00288002
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00288002
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01584830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given 3 weeks on/1 week off (160 mg od po.)
Trial: NCT00972322
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to MK-8245 twice daily for 28 days
Trial: NCT02251249
Drug: Paracetamol concentration time curve from 0 to 120 min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
Trial: NCT00135473
Drug: 10% Hemohes® (10% Hydroxyethyl starch)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135473
Drug: Sterofundin® (Ringer lactate solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135473
Drug: Actrapid® (Insulin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01836939
Drug: TSO 2500
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
Trial: NCT03108963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
Trial: NCT01836939
Drug: TSO 7500
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
Trial: NCT01372839
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Trial: NCT01225380
Drug: GS-9190 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching GS-9190 capsule BID, 24 weeks